ACCESS Newswire

mymediset

Share
mymediset LiveSync: mymediset and Terso Solutions Announce a New Partnership to Deliver a Revolutionary Supply Chain Platform for Live Consignment Tracking and Automation

FREIBURG, GERMANY / ACCESSWIRE / March 28, 2024 / mymediset, the leading provider of SAP solutions for the medical device industry, and Terso Solutions, the leading provider of RFID tracking solutions for the life sciences and healthcare markets, have today announced a new partnership to launch mymediset LiveSync, a revolutionary platform that will transform the way consigned inventory is identified, managed and tracked across mission-critical supply chains worldwide.

The new platform combines mymediset's cloud-based SAP automation solutions and Terso's RAIN RFID enclosures (cabinets, freezers, refrigerators) and sensors to provide real-time visibility and control of consigned products in the life sciences industries, such as medical devices, loaner kits, and pharmaceuticals. The platform, which will be launched in Q3/2024, is the first of its kind to combine live tracking and inventory data for medical and pharmaceutical consignments that is integrated into an intelligent, open, and extensible platform that provides complete visibility and control across the full product lifecycle from manufacture-to-disposal or recycling.

"This co-innovation initiative was brought together by mymediset and Terso Solutions in response to the multi-billion-dollar problem of inventory over-stocking caused by lack of real-time visibility and missing tracking data 'dead zones' that occur as consignments cycle through the different supply chain systems operated by manufacturers, distributors, and hospitals," said Michael Knauer, CEO & Founder of mymediset.

Joe Pleshek, CEO and President of Terso Solutions added: "Current industry estimates project, that several billion dollar of excess, unrecorded, or lost inventory may exist to assure product availability in mission-critical healthcare and lifesciences environments. With consignment records spanning numerous siloed systems and fragmented data sources, activities such as integrated planning, inventory rationalization and efficient automation of operations such as replenishment, disposal and recycling have so far been too costly and too complex for any one operator to resolve."

Knauer continued: "With our new mymediset LiveSync solution, we can now connect MedTech and Pharma manufacturers, distributors, and hospitals in a seamless, visible lifecycle, enabling customers to see, know, optimize, and automate every consignment wherever it is in the cycle. This provides an invaluable solution that can be used to rationalize inventory levels, reduce costs, improve patient safety, and comply with regulatory requirements and it provides the fundamental building block for our customers to create next-generation supply chains."

mymediset LiveSync Benefits:

  • Brings together the market leading capabilities of mymediset and Terso Solutions. Combining mymediset's platform, a software-as-a-service (SaaS) solution and Terso's RAIN RFID enabled enclosures and sensors, to automatically capture consignment movements in real time. Automates the entire consignment process, from order placement to invoicing, using smart algorithms and data analytics to manage complex consignment and field inventory processes inside SAP.
  • Connects all stakeholders involved in the consignment cycle and provides them with actionable insights and reports on inventory status, consumption, expiration, and replenishment.
  • Terso's RFID enclosures and sensors are connected to the cloud and transmit the inventory data to mymediset's platform in real-time, eliminating the need for manual scanning, counting, or reporting. The enclosures provide secure access control and track environmental data including temperature to ensure product integrity.
  • A seamless and scalable cloud-based SaaS solution for consignment automation that will benefit both suppliers and customers. The product will enable suppliers to increase sales, improve cash flow, and enhance customer satisfaction by ensuring the right products are available at the right time and place.
  • Enable customers to reduce inventory waste, avoid stock-outs, and improve patient outcomes by having access to the latest supplies, equipment, and devices, instantly locatable at the touch of a button.

Commenting on the partnership both CEOs pointed to the potential for customers to gain significant value from the new combination:

"We are very excited to partner with Terso Solutions and leverage their expertise and innovation in RFID technology. Together, we will offer a unique and powerful platform that will solve the challenges and inefficiencies of consignment management in the medical and life sciences industries. Our product will create value for our customers and help them achieve new levels of operational excellence and competitive advantage as they take on the challenge of running leaner, faster inventory lifecycles in next-generation supply chains driven by real-time data and assisted by AI. Two market leaders have come together to bring real-time transparency to the healthcare and life sciences industries. Finally, now we know what, where, and when products have been consumed, in real time" said Knauer.

"We are thrilled to partner with mymediset and integrate their SAP-based Enterprise SaaS platform with our RFID enabled solutions. Both mymediset and Terso have a proven track record of delivering consignment automation solutions that are trusted in the most demanding, mission-critical environments. Our product will provide a complete and end-to-end solution for consignment automation that will revolutionize the way consigned inventory is managed and tracked. With this innovative solution, We Know Now." said Pleshek.

The new product will be available for pre-order in April 2024 and will be launched in Q3 2024.

About mymediset

mymediset is the leading provider of cloud-based automation solutions for the medical device industry that specializes in managing complex loan, consignment, and field inventory processes inside SAP®. mymediset offers a platform that connects medical device and pharma manufacturers, distributors, hospitals, and clinics, and enables them to manage and track their consigned inventory in real-time. mymediset helps its customers reduce costs, increase sales, and optimize inventory levels, while ensuring compliance and patient safety.

About Terso Solutions, Inc.

Terso Solutions, Inc. is the leading provider of automated inventory management solutions for tracking high-value medical and scientific products in healthcare and life science. Terso is backed by 18 years of RFID product development and implementation experience, with a product line that includes RAIN RFID cabinets, refrigerators, freezers (-86°C to -5°C), read points, mobile solutions, and rooms. Terso has deployed over 3,500 RAIN RFID-enabled devices worldwide and provides inventory automation at over 1,000 U.S. healthcare facilities. Headquartered in Madison, WI, with additional offices in Walldorf, Germany and Tokyo, Japan, Terso Solutions, Inc. is a wholly owned subsidiary of the Promega Corporation.

For press inquiries, please contact:

mymediset:
Gloriela Rosas
LiveSync@mymediset.cloud
Phone:
North America: +1 (617) 506 9850
Europe: +49 (761) 556-5580
Terso Solutions:
Katie Anderson
katie.anderson@tersosolutions.com
Phone:+1 (608) 960-7376
For more information, please visit:
mymediset:https://mymediset.net/
https://mymediset.net/livesync/
Terso Solutions:www.tersosolutions.com

SOURCE: mymediset



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release

MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye

IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release

Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres

General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release

DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper

Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye